Bär & Karrer acted as legal adviser to Octavian and Helvetische Bank in this transaction and Vischer AG advised Kuros Biosciences.
Kuros Biosciences, a life science company focusing on the development and marketing of orthobiologics, completed a capital increase by way of a rights offering to its shareholders. 50.2% of the shareholders of Kuros Biosciences exercised their subscription rights in the rights offering.
The remaining 4,192,530 offered shares were placed in the market and an additional tranche of 1,915,203 shares was sold to Optiverder B.V. The offer price was set at CHF 1.80 per share.
Bär & Karrer team included Thomas U. Reutter (Picture), Alexander von Jeinsen, Carlo Hunter, Christoph Suter and David Weimann.
VISCHER AG team included Matthias Staehelin, Sebastian Flückiger, Nadia Tarolli and Adrian Briner.
Involved fees earner: Carlo Hunter – Bär & Karrer; Thomas Reutter – Bär & Karrer; Christoph Suter – Bär & Karrer; Alexander von Jeinsen – Bär & Karrer; David Weimann – Bär & Karrer; Adrian Briner – VISCHER AG; Sebastian Flückiger – VISCHER AG; Matthias Staehelin – VISCHER AG; Nadia Tarolli – VISCHER AG;